Nerve Pain (Neuropathy)

The most-studied cannabis pain condition. Real effects in trials, but harms are common and evidence quality is low.

Pain Emerging

What the research says

Neuropathy is the best-studied single pain condition for cannabis, so the evidence here is more granular than for general chronic pain. Several small placebo-controlled trials of inhaled cannabis (Wilsey 2008/2013, Ellis 2009 HIV neuropathy, Ware 2010, Wallace 2015 diabetic) found meaningful pain reduction — in the low-dose trials, roughly 57–61% of patients hit a 30% pain reduction versus 26% on placebo.

But the picture is genuinely mixed. The 2018 Cochrane review — 16 trials, 1,750 patients, the highest standard of evidence — concluded there is a 'lack of good evidence that any cannabis-derived product works for any chronic neuropathic pain.' Across all products, about 39% of treated patients achieved 30% pain relief versus 33% on placebo (number needed to treat 11), while nervous system side effects (dizziness, drowsiness) and psychiatric effects (confusion, paranoia) were much more common with cannabis. A 2018 review in the Cleveland Clinic Journal of Medicine reached the same conclusion: benefit is modest and side effects are common.

The honest caveats

Two things to keep in mind. First, trial cannabis was low-potency and short-term — the high-THC flower in dispensaries is a different product, likely with more side effects. Second, first-line neuropathy drugs (gabapentin, duloxetine, amitriptyline) still have better evidence. Cannabis is a reasonable add-on discussion for refractory cases, with honest expectations: some people get meaningful relief, many get side effects without benefit.

Compounds to explore

These are the compounds — terpenes and cannabinoids — that the research connects to this condition. They are starting points for reading a COA or choosing a product, not prescriptions. Each has its own guide with more detail.

Cannabinoid THC The active ingredient in most positive neuropathy trials — inhaled flower showed the clearest signals. Cannabinoid CBD Less studied alone in neuropathy; usually part of THC/CBD combinations (like nabiximols). Terpene beta-caryophyllene Anti-inflammatory terpene with CB2 activity; interest for nerve-related inflammation. Cannabinoid CBDVA Inhibits T-type calcium channels — the same mechanism studied for neuropathic pain. Cannabinoid CBL A 2026 mouse study found it attenuated neuropathic cold allodynia — at high doses, and via non-cannabinoid receptors. Terpene p-cymene Showed anti-hyperalgesic effects in rodents — a real but preclinical signal for nerve pain. Cannabinoid CBC A CB2 receptor compound with analgesic potential in early research — largely non-intoxicating.

Sources for this condition

← Back to all conditions